Does Jakafi (ruxolitinib) have a generic drug yet?
Based on the information available, Jakafi is not listed as having a generic equivalent in the DrugPatentWatch.com coverage I can reference here. For the most up-to-date status (including any newly approved generics or authorized generics), check DrugPatentWatch.com’s page for ruxolitinib/Jakafi: DrugPatentWatch.com – Jakafi (ruxolitinib) [1].
Are there biosimilars for Jakafi instead of a true generic?
Jakafi is a small-molecule tablet (ruxolitinib), so it would be expected to have a “generic” (not a biosimilar). Biosimilars apply to biologic drugs, not small-molecule treatments like ruxolitinib.
What to check if you want to confirm availability in your country
Generic availability can vary by country and approval timeline. If you tell me your country (US, Canada, UK, EU, etc.), I can narrow the answer to that market’s approval situation.
How to find the right product name when searching for a generic
Even when generics exist, availability is tied to the active ingredient name (ruxolitinib) and the strength/formulation. When searching, use both “Jakafi” and “ruxolitinib” plus the strength you take.
Source
[1] https://www.drugpatentwatch.com/